Ushering In a New Era of Drug Prices, Part 2: 340B Reform

Unconventional pathways and creative policymaking have already upended the pharmaceutical sector this year, and more changes are expected that have the potential to reshape U.S. drug pricing permanently. Part two of this two part series analyzes developments in 340B program reform, including a controversial HRSA pilot.